Inappropriate antidopaminergic drug use in Parkinsońs disease inpatients

Current Drug Therapy

Volumn 7, Issue 3, 2012, Pages 164-169

  Domingo Echaburu, Saioa ^a   Lertxundi, Unax ^a   Gonzalo Olazabal, Elena ^a   Peral Aguirregoitia, Javier ^b   Peña Bandrés, Iñaki ^c  

^a Pharmacy Service   (Spain)

^b Hospital Galdakao Usansolo   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

Antidopaminergics; Antiemetics; Antipsychotics; Hospitalization; Inappropriate drug use; Parkinso s disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINITAPRIDE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CLINICAL ARTICLE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INAPPROPRIATE PRESCRIBING; MALE; MEDICAL RECORD REVIEW; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 84872250932     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488512803988067     Document Type: Review

References (25)

1. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson's disease. Intern Med J 2006; 36: 524-6.
2. Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson's disease patient: systematic review. Mov Disord 2011; 26: 197-208.
3. Aminoff MJ, Christine CW, Friedman JH, et al. National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease. Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord 2011; 17: 139-45.
4. Chou KL, Zamudio J, Schmidt P, et al. Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord 2011; 17: 440-5.
5. Derry CP, Shah KJ, Caie L, Counsell CE. edication management in people with Parkinson's disease during surgical admissions. Postgrad Med J 2010; 86: 334-7.
6. Wu LJ, Ward CT, Moore S, et al. Assessment of medical care for patients with Parkinson's disease during hospitalization. Mov Disord 2009; 24(suppl 1): S378-9. Abstract.
7. Magdalinou KN, Martin A, Kessel B. Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital. Parkinsonism Relat Disord 2007; 13: 539-40.
8. Jones SL, Hindle JV. Parkinson's disease in the acute hospital. Clin Med 2011; 11: 84-88.
9. Gerlach OH, Broen MP, van Domburg PH, Vermeij AJ, Weber WE. Deterioration of Parkinsońs disease during hospitalization: survey of 684 patients. BMC Neurol 2012; 12: 13.
10. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996e1002.
11. Friedman JH. Parkinson's disease psychosis 2010: A review article. Parkinsonism Relat Disord 2010; 16: 553-60.
12. Friedman JH. Recommendations on the drug treatment of psychosis in Parkinson's disease. Am J Med 2010; 123: e19; author reply e21.
13. Robottom BJ, Shulman LM, Anderson KE, Weiner WJ. Metoclopramide-induced encephalopathy in Parkinson disease. South Med J 2010; 103: 178-80.
14. Lertxundi U, Peral J, Mora O, Domingo-Echaburu S, Martínez Bengoechea MJ, García-Moncó JC. Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease. Am J Health Syst Pharm 2008; 65: 414-9.
15. Spencer R, Serumaga B. Prescribing antiemetics for patients with Parkinson's. Prescriber 2011; 22: 48-49.
16. ATC/DDD Index 2012. Available at: http: //www.whocc.no/atc_ ddd_index/. [Accessed 8/2/2012].
17. Parkinson's: Key information for hospital pharmacists. Available at: http: //www.parkinsons.org.uk/search.aspx?terms=pharmacist. [Accessed: 8/2/2012].
18. Cosentino M, Martignoni E, Michielotto D, et al. Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Serv Res 2005; 5: 26-33.
19. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson's disease psychosis. Arch Neurol 2011; 68: 899-904.
20. Safety Labelling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)-July 2011. Available at: http: //www.fda.gov/Safety/MedWatch/SafetyInformation/ucm267700.htm. [Accessed: 8/2/2012].
21. Domperidona y riesgo cardiaco. Nota informativa del comité de Seguridad de Medicamentos de Uso Humano. Agencia Española del Medicamento. Available at: http: //www.aemps.gob.es/informa/ notasInformativas/medicamentosUsoHumano/seguridad/2011/NIMUH_ 24-2011.htm. [Accessed: 8/12/2012].
22. Bergareche A, De La Puente E, López de Munain A, et al. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol 2004; 251(3): 340-5.
23. Number of patients > 65 years in Comarca Alto Deba. http: // www.eustat.es/elementos/ele0003200/ti_Poblacion_de_la_CA_de_ Euskadi_por_ambitos_territoriales_y_sexo_31-XII--009/tbl0003278_c.html#axzz1bKwm4tNE [Accessed 20/10/2011].
24. Parkinson's UK. "Get It on Time" campaign. Available at: www.parkinsons.org.uk [accessed 8/2/2012]
25. O'Malley KJ, Cook KF, Price MD, Raiford Wildes K, Hurdle JF, Ashton CM. Measuring Diagnoses: ICD Code Accuracy. Health Serv Res 2005; 40: 1620-1639.